Your browser is no longer supported. Please, upgrade your browser.
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
IndexS&P 500 P/E27.34 EPS (ttm)8.34 Insider Own0.10% Shs Outstand257.88M Perf Week0.66%
Market Cap58.12B Forward P/E16.84 EPS next Y13.55 Insider Trans10.83% Shs Float253.83M Perf Month4.34%
Income2.18B PEG1.76 EPS next Q3.30 Inst Own93.80% Short Float1.15% Perf Quarter21.91%
Sales7.13B P/S8.15 EPS this Y128.00% Inst Trans0.23% Short Ratio1.55 Perf Half Y13.76%
Book/sh36.96 P/B6.17 EPS next Y5.03% ROA17.90% Target Price264.68 Perf Year-4.00%
Cash/sh27.31 P/C8.35 EPS next 5Y15.50% ROE23.90% 52W Range176.36 - 242.99 Perf YTD3.86%
Dividend- P/FCF30.29 EPS past 5Y45.30% ROI26.40% 52W High-6.14% Beta0.59
Dividend %- Quick Ratio4.50 Sales past 5Y43.20% Gross Margin87.90% 52W Low29.33% ATR4.37
Employees3400 Current Ratio4.60 Sales Q/Q29.00% Oper. Margin37.20% RSI (14)65.06 Volatility2.11% 1.90%
OptionableYes Debt/Eq0.00 EPS Q/Q29.80% Profit Margin30.50% Rel Volume1.15 Prev Close228.61
ShortableYes LT Debt/Eq0.05 EarningsJan 26 AMC Payout0.00% Avg Volume1.88M Price228.08
Recom2.10 SMA201.54% SMA509.36% SMA20013.48% Volume2,155,179 Change-0.23%
Jan-20-22Upgrade BMO Capital Markets Market Perform → Outperform $202 → $274
Dec-09-21Initiated Wells Fargo Overweight $270
Nov-19-21Initiated BMO Capital Markets Market Perform $202
Nov-19-21Downgrade Piper Sandler Overweight → Neutral $323 → $218
Sep-09-21Downgrade Stifel Buy → Hold $244 → $213
Sep-07-21Downgrade Morgan Stanley Equal-Weight → Underweight $202
Jul-20-21Downgrade SVB Leerink Mkt Perform → Underperform $170
Jul-19-21Resumed Wolfe Research Outperform $252
Jul-01-21Initiated Raymond James Mkt Perform
Jun-11-21Downgrade Daiwa Securities Outperform → Neutral $210
Feb-23-21Upgrade Robert W. Baird Neutral → Outperform $220 → $252
Feb-02-21Reiterated H.C. Wainwright Buy $315 → $275
Dec-30-20Initiated Daiwa Securities Outperform $250
Nov-30-20Upgrade RBC Capital Mkts Sector Perform → Outperform $247 → $267
Nov-20-20Initiated Bernstein Outperform $225
Oct-28-20Initiated UBS Buy $287
Jul-31-20Reiterated H.C. Wainwright Buy $295 → $315
Jul-08-20Downgrade Morgan Stanley Overweight → Equal-Weight $300
Apr-30-20Reiterated H.C. Wainwright Buy $270 → $295
Apr-28-20Downgrade RBC Capital Mkts Outperform → Sector Perform $250 → $260
Jan-22-22 08:46AM  
Jan-21-22 05:50PM  
05:38PM  
09:08AM  
06:50AM  
Jan-20-22 01:38PM  
01:05PM  
12:10PM  
11:20AM  
10:44AM  
09:30AM  
08:08AM  
04:30AM  
Jan-19-22 06:00PM  
05:38PM  
01:38PM  
10:27AM  
06:53AM  
05:21AM  
Jan-18-22 05:38PM  
04:15PM  
04:05PM  
10:34AM  
Jan-17-22 01:58PM  
Jan-14-22 09:38AM  
06:10AM  
Jan-13-22 05:38PM  
Jan-12-22 10:42AM  
Jan-11-22 12:45PM  
10:04AM  
03:01AM  
Jan-10-22 06:00PM  
Jan-09-22 07:23PM  
09:27AM  
Jan-07-22 09:06PM  
01:38PM  
06:37AM  
Jan-06-22 09:38AM  
Jan-05-22 01:38PM  
05:52AM  
Jan-04-22 05:50PM  
04:05PM  
Jan-03-22 06:00AM  
Jan-01-22 06:45AM  
Dec-31-21 07:03AM  
Dec-30-21 08:00AM  
Dec-29-21 05:45PM  
Dec-27-21 01:38PM  
Dec-26-21 09:31AM  
Dec-21-21 01:30PM  
Dec-20-21 08:38PM  
05:45PM  
Dec-19-21 05:55AM  
Dec-17-21 11:38PM  
04:38PM  
08:37AM  
Dec-15-21 02:38AM  
Dec-14-21 11:38PM  
05:45PM  
Dec-13-21 03:38PM  
Dec-12-21 06:55AM  
Dec-11-21 03:09PM  
05:38AM  
Dec-10-21 01:38PM  
06:00AM  
Dec-09-21 08:41AM  
Dec-08-21 07:38PM  
07:38PM  
Dec-07-21 03:16PM  
06:12AM  
Dec-05-21 05:51AM  
Dec-04-21 05:25AM  
Dec-03-21 07:24AM  
06:15AM  
Dec-02-21 11:31AM  
10:28AM  
10:13AM  
10:00AM  
10:00AM  
05:55AM  
Dec-01-21 04:36PM  
04:18PM  
12:28PM  
11:06AM  
10:27AM  
07:30AM  
Nov-29-21 06:00AM  
Nov-26-21 07:42AM  
Nov-23-21 12:01PM  
Nov-20-21 07:00AM  
Nov-19-21 06:00AM  
Nov-17-21 11:15AM  
10:45AM  
09:53AM  
Nov-15-21 09:04AM  
Nov-12-21 07:27AM  
Nov-11-21 06:47AM  
06:00AM  
Nov-09-21 01:41PM  
Nov-08-21 10:17AM  
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; Mammoth Biosciences; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sachdev AmitEVP, Chief Patient OfficerNov 15Sale187.19519,54731,928Nov 16 04:07 PM
Arbuckle Stuart AEVP, COONov 15Sale187.26356241,103Nov 16 04:05 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 15Sale187.22346,36533,589Nov 16 04:04 PM
Kewalramani ReshmaCEO & PresidentAug 19Buy195.6510,0001,956,49273,754Aug 23 08:30 AM
SACHS BRUCE IDirectorAug 02Buy197.9115,0002,968,65041,210Aug 04 04:05 PM
Bhatia Sangeeta N.DirectorJun 02Sale209.69559117,2165,191Jun 04 04:03 PM
Arbuckle Stuart AEVP, Chief Comm & Ops OfficerMay 17Sale216.4110923,58941,103May 19 04:04 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 17Sale216.367917,09333,589May 19 04:02 PM
Sanna BastianoEVP, Cell & Genetic TherapiesMay 17Sale216.3411224,23034,108May 19 04:10 PM
Sachdev AmitEVP, Chief Patient OfficerMay 17Sale216.35459,73640,133May 19 04:08 PM
Sanna BastianoEVP, Cell & Genetic TherapiesMay 03Sale218.43960209,69134,108May 05 09:23 PM
Sachdev AmitEVP, Chief Patient OfficerApr 27Option Exercise86.523,884336,04444,017Apr 29 04:03 PM
Sachdev AmitEVP, Chief Patient OfficerApr 27Sale216.063,884839,19340,133Apr 29 04:03 PM
Sanna BastianoEVP, Cell & Genetic TherapiesApr 05Sale214.141,686361,04635,834Apr 07 04:04 PM
Liu JoySVP, General CounselMar 05Sale209.695,1411,078,0188,253Mar 08 04:10 PM
Silva Paul MSVP & Chief Accounting OfficerMar 01Sale211.452,782588,2559,884Mar 02 04:07 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 25Sale213.393,028646,13933,589Feb 26 04:03 PM
Silva Paul MSVP & Chief Accounting OfficerFeb 25Sale213.471,080230,55114,884Feb 26 04:23 PM
Sachdev AmitEVP, Chief Patient OfficerFeb 25Sale213.423,586765,30740,133Feb 26 04:20 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffFeb 25Sale213.383,028646,12530,837Feb 26 04:18 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerFeb 25Sale213.543,634775,98941,103Feb 26 04:07 PM
Silva Paul MSVP & Chief Accounting OfficerFeb 18Sale211.834,295909,82816,828Feb 19 04:21 PM
Sachdev AmitEVP, Chief Patient OfficerFeb 18Sale211.839,2641,962,36646,665Feb 19 04:20 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffFeb 18Sale211.837,8251,657,55636,281Feb 19 04:18 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerFeb 18Sale211.827,8251,657,48147,635Feb 19 04:08 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 18Sale211.837,8251,657,59039,033Feb 19 04:05 PM
Sachdev AmitEVP, Chief Patient OfficerFeb 11Sale210.554,460939,06863,542Feb 16 04:20 PM
Silva Paul MSVP & Chief Accounting OfficerFeb 11Sale210.571,498315,43723,863Feb 16 04:24 PM
Sanna BastianoEVP, Cell & Genetic TherapiesFeb 11Sale210.561,686355,01238,864Feb 16 04:22 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffFeb 11Sale210.564,318909,17950,346Feb 16 04:15 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerFeb 11Sale210.555,1561,085,59361,700Feb 16 04:07 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 11Sale210.545,2831,112,27453,098Feb 16 04:02 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffFeb 05Option Exercise86.521,930166,98459,157Feb 09 07:44 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffFeb 05Sale215.001,930414,95057,227Feb 09 07:44 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerFeb 03Option Exercise86.521,554134,45271,511Feb 05 04:43 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffFeb 03Option Exercise86.5240034,60857,627Feb 05 04:52 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffFeb 03Sale216.5640086,62457,227Feb 05 04:52 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerFeb 03Sale213.741,554332,14669,957Feb 05 04:43 PM